Abstract
The practical synthesis of 3-(trifluoromethyl)-triazolopiperazine the key intermediate of Sitagliptin and 3- (trifluoromethyl)-triazolopyridine was carried out employing industrially feasible transformations. The other advantage of this method is the new environment friendly approach to synthesize triazolopiperazine and triazolopyridines by eliminating the commonly used trifluoroacetic anhydride and polyphosphoric acid.
Keywords: Sitagliptin, 3-(trifluoromethyl)-triazolopiperazine, 3-(trifluoromethyl)-triazolopyridine, antidiabetic.
Letters in Organic Chemistry
Title:Exploring the Unexplored Practical and Alternative Synthesis of 3- (Trifluoromethyl)-Triazolopiperazine the Key Intermediate for Sitagliptin
Volume: 10 Issue: 5
Author(s): Lakshmikant H. Nitlikar, Sunil N. Darandale and Devanand B. Shinde
Affiliation:
Keywords: Sitagliptin, 3-(trifluoromethyl)-triazolopiperazine, 3-(trifluoromethyl)-triazolopyridine, antidiabetic.
Abstract: The practical synthesis of 3-(trifluoromethyl)-triazolopiperazine the key intermediate of Sitagliptin and 3- (trifluoromethyl)-triazolopyridine was carried out employing industrially feasible transformations. The other advantage of this method is the new environment friendly approach to synthesize triazolopiperazine and triazolopyridines by eliminating the commonly used trifluoroacetic anhydride and polyphosphoric acid.
Export Options
About this article
Cite this article as:
Nitlikar Lakshmikant H., Darandale Sunil N. and Shinde Devanand B., Exploring the Unexplored Practical and Alternative Synthesis of 3- (Trifluoromethyl)-Triazolopiperazine the Key Intermediate for Sitagliptin, Letters in Organic Chemistry 2013; 10 (5) . https://dx.doi.org/10.2174/1570178611310050008
DOI https://dx.doi.org/10.2174/1570178611310050008 |
Print ISSN 1570-1786 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6255 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Relationship Between Oncogene Expression and Clinical Outcome in Endometrial Carcinoma
Current Cancer Drug Targets Inhibition of Multidrug Resistance of Cancer Cells by Natural Diterpenes, Triterpenes and Carotenoids
Current Pharmaceutical Design Recent Patents on Heat Shock Proteins Targeting Antibodies
Recent Patents on Anti-Cancer Drug Discovery Aquaporin Biology and Nervous System
Current Neuropharmacology Gist Representations and Communication of Risks about HIV-AIDS: A Fuzzy-Trace Theory Approach
Current HIV Research Pharmacokinetics and Disposition of Various Drug Loaded Biodegradable Poly(Lactide-Co-Glycolide) (PLGA) Nanoparticles
Current Drug Metabolism Psoriasin, A Multifunctional Player in Different Diseases
Current Protein & Peptide Science Mesenchymal Stem Cells of Dental Origin-Their Potential for Antiinflammatory and Regenerative Actions in Brain and Gut Damage
Current Neuropharmacology The Prolyl-Aminodipeptidases and their Inhibitors as Therapeutic Targets for Fibrogenic Disorders
Mini-Reviews in Medicinal Chemistry Novel Targets for Antiinflammatory and Antiarthritic Agents
Current Pharmaceutical Design Co-Delivery of Epirubicin and siRNA Using Functionalized Mesoporous Silica Nanoparticles Enhances In vitro and In vivo Drug Efficacy
Current Drug Delivery MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Current Pharmaceutical Design Cancer Drug Discovery Targeting Histone Methyltransferases: An Update
Current Medicinal Chemistry The Pathophysiological Role of PEDF in Bone Diseases
Current Molecular Medicine Meet Our Editorial Board Member
Current Cancer Drug Targets Anti-cancer Drug Delivery Using Metal Organic Frameworks (MOFs)
Current Medicinal Chemistry P2Y Purinoceptors as Potential Emerging Therapeutical Target in Vascular Disease
Current Pharmaceutical Design Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective Enzyme Inhibitors
Current Drug Targets Role of EGFR Inhibitors in the Treatment of Central Nervous System Metastases from Non-Small Cell Lung Cancer
Current Cancer Drug Targets Melatonin as a Pleiotropic Molecule with Therapeutic Potential for Type 2 Diabetes and Cancer
Current Medicinal Chemistry